Logistics Reply: AI-powered assistant LEApedia wins 'Best Product LogiMAT 2024' Award
22.3.2024 11:30:00 EET | Business Wire | Press release
LEApedia, an AI-based assistant for warehouse management systems (WMS), won the coveted "Best Product LogiMAT 2024" award in the "Software, Communication & IT" category at the opening ceremony of LogiMAT 2024. The application is seamlessly integrated into the LEA Reply™ cloud-native SaaS WMS solution, offered by Logistics Reply, the Reply Group specialists in delivering innovative software solutions for the digital supply chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322257679/en/
LEApedia revolutionizes the way you interact with your warehouse management system (WMS) and other supply chain tools, with the integration of a powerful multi-agent AI engine to enhance efficiency, streamline operations, and unlock new insights. LEApedia facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. (Graphic: Business Wire)
The award, which is considered one of the most coveted in the intralogistics industry, is presented at the International Trade Fair for Intralogistics and recognizes outstanding achievements in the logistics sector that significantly optimise internal logistics processes, reduce costs and increase productivity.
LEApedia, which helps to improve logistics management processes, stands at the forefront of warehouse management system (WMS) innovation powered by an advanced multi-agent AI engine. This engine facilitates the analysis of vast datasets, enabling the identification of patterns and insights that were previously unattainable. At its core, LEApedia leverages a state-of-the-art Language Model, designed to interpret and respond to natural language queries and commands. This capability ensures users can interact with the system efficiently, significantly improving usability and accessibility.
Furthermore, LEApedia's smart search functionality allows for quick and intuitive access to information, ranging from specific terms to complex process descriptions. This feature is instrumental in navigating the system, ensuring users can find the information they need with unprecedented ease and speed. LEApedia enhances the system's efficiency and user-friendliness, setting a new standard for WMS solutions.
LEApedia is tailored to the specific needs and software environment of each customer. This makes it suitable for small businesses as well as medium-sized handling centres and large players. The module can be integrated into the system in a very short timeframe without slowing down or interrupting operations. It can also be updated during regular business without disruptions.
"The LogiMAT 2024 award is further proof of the tremendous performance of our WMS solution, which we are continuously evolving to take time-to-value and quality to new levels and support our customers in every step of their digital transformation journey. Technologies such as generative AI and machine learning help improve supply chain visibility and enable proactive decision making. The LEApedia AI-powered assistant offers users new opportunities to efficiently scale their WMS during ongoing warehouse operations and compete in the dynamic logistics industry," concluded Enrico Nebuloni, Executive Partner at Reply.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Logistics Reply
Logistics Reply provides cutting-edge software solutions that help companies achieve an efficient and more connected digital supply chain where different systems, partners, humans and machines seamlessly interact embracing the use of next-generation technologies such as AI, robotics, wearables and IoT. Logistics Reply accompanies its customers in this transformation journey ensuring rapid time-to-value and long-term quality results thanks to over 20 years of experience and deep knowledge of technologies and supply chain processes. www.lea.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322257679/en/
Contact information
Media:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Sandra Dennhardt
s.dennhardt@reply.com
Tel. +49 170 4546229
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom